NO973529L - Anvendelse av 5'-substituerte nukleosider for å hemme resistensdannelse ved cytostatisk behandling og medikamenter inneholdende slike nukleosider - Google Patents

Anvendelse av 5'-substituerte nukleosider for å hemme resistensdannelse ved cytostatisk behandling og medikamenter inneholdende slike nukleosider

Info

Publication number
NO973529L
NO973529L NO973529A NO973529A NO973529L NO 973529 L NO973529 L NO 973529L NO 973529 A NO973529 A NO 973529A NO 973529 A NO973529 A NO 973529A NO 973529 L NO973529 L NO 973529L
Authority
NO
Norway
Prior art keywords
nucleosides
cytostatic
bvdu
cytostatic treatment
resistance
Prior art date
Application number
NO973529A
Other languages
English (en)
Other versions
NO315258B1 (no
NO973529D0 (no
Inventor
Rudolf Fahrig
Angela Steinkampzucht
Original Assignee
Fraunhofer Ges Forschung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545892A external-priority patent/DE19545892A1/de
Application filed by Fraunhofer Ges Forschung filed Critical Fraunhofer Ges Forschung
Publication of NO973529D0 publication Critical patent/NO973529D0/no
Publication of NO973529L publication Critical patent/NO973529L/no
Publication of NO315258B1 publication Critical patent/NO315258B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19973529A 1995-02-01 1997-07-31 Anvendelse av 5'-substituerte nukleosider NO315258B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19503152 1995-02-01
DE19545892A DE19545892A1 (de) 1995-12-08 1995-12-08 Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU
PCT/DE1996/000169 WO1996023506A1 (de) 1995-02-01 1996-01-31 Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside

Publications (3)

Publication Number Publication Date
NO973529D0 NO973529D0 (no) 1997-07-31
NO973529L true NO973529L (no) 1997-10-01
NO315258B1 NO315258B1 (no) 2003-08-11

Family

ID=26012025

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19973529A NO315258B1 (no) 1995-02-01 1997-07-31 Anvendelse av 5'-substituerte nukleosider

Country Status (12)

Country Link
US (1) US6589941B1 (no)
EP (1) EP0806956B1 (no)
JP (1) JPH11502515A (no)
KR (1) KR100330602B1 (no)
AT (1) ATE222765T1 (no)
BR (1) BR9607109A (no)
DE (1) DE59609590D1 (no)
DK (1) DK0806956T3 (no)
ES (1) ES2180730T3 (no)
NO (1) NO315258B1 (no)
PT (1) PT806956E (no)
WO (1) WO1996023506A1 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008110A1 (en) * 1997-08-08 1999-02-18 Newbiotics, Inc. Methods and compositions for overcoming resistance to biologic and chemotherapy
IL137164A0 (en) 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
DE19842578A1 (de) * 1998-09-17 2000-03-23 Max Delbrueck Centrum Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
BR0012676A (pt) 1999-07-22 2003-07-01 Newbiotics Inc Métodos para tratamento de tumores resistentes a terapia
US20030212037A1 (en) * 2000-12-21 2003-11-13 Christopher Boyer Use of bvdu for inhibiting the growth of hyperproliferative cells
EP1251836A2 (en) * 1999-12-23 2002-10-30 NewBiotics, Inc. Use of bvdu for inhibiting the growth of hyperproliferative cells
US7138388B2 (en) 2001-01-19 2006-11-21 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
DE10313035A1 (de) * 2003-03-24 2004-10-07 Resprotect Gmbh Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen
US20060269596A1 (en) * 2005-01-12 2006-11-30 Gary Liversidge Controlled release compositions comprising an acylanilide
HUP0600042A3 (en) * 2006-01-19 2012-12-28 Debreceni Egyetem New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
DE102006037786A1 (de) * 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090068286A1 (en) * 2007-09-11 2009-03-12 Resprotect, Gmbh Method of treating cancer by administration of 5-substituted nucleosides
EP2135601A1 (en) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices
DE102008030091B4 (de) 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
NZ607996A (en) 2010-09-22 2014-07-25 Alios Biopharma Inc Substituted nucleotide analogs
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1069096A (en) * 1962-11-23 1967-05-17 Ile De Rech S Scient Et Ind So New organic derivatives of nucleotides and method for their manufacture
GB1473148A (no) * 1974-09-16 1977-05-11
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
NL8700366A (nl) * 1987-02-13 1988-09-01 Stichting Rega V Z W Combinatie van fu met bvdu als middel tegen adenocarcinoom.
US5250296A (en) 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5831064A (en) 1996-07-25 1998-11-03 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof
IL137164A0 (en) 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents

Also Published As

Publication number Publication date
KR100330602B1 (ko) 2002-08-22
DK0806956T3 (da) 2003-01-06
US6589941B1 (en) 2003-07-08
ES2180730T3 (es) 2003-02-16
KR19980701862A (ko) 1998-06-25
PT806956E (pt) 2003-01-31
WO1996023506A1 (de) 1996-08-08
JPH11502515A (ja) 1999-03-02
NO315258B1 (no) 2003-08-11
MX9705758A (es) 1997-10-31
ATE222765T1 (de) 2002-09-15
EP0806956B1 (de) 2002-08-28
EP0806956A1 (de) 1997-11-19
NO973529D0 (no) 1997-07-31
DE59609590D1 (de) 2002-10-02
BR9607109A (pt) 1997-11-04

Similar Documents

Publication Publication Date Title
NO973529L (no) Anvendelse av 5'-substituerte nukleosider for å hemme resistensdannelse ved cytostatisk behandling og medikamenter inneholdende slike nukleosider
CA2225808A1 (en) Silver-based pharmaceutical compositions
LU91751I2 (fr) Asenapin et ses dérivés pharmaceutiquement acceptables (SYCREST®)
CA2223625A1 (en) Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
PL309604A1 (en) Pharmaceutical composition for treating nicotin dependence
KR880011197A (ko) 위장장해를 치료하기 위한 조성물 및 방법
IL107134A0 (en) Pharmaceutical compositions for the treatment of parkinson's disease
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
CA2283399A1 (en) Pyridazinones as inhibitors of cyclooxygenase-2
ES2180564T3 (es) 2-fenil-3-azoilbenzotiofenos para aumentar la expresion de trombomodulina.
WO1993007866A3 (en) Compositions and methods for therapy and prevention of cancer, aids, and anemia
DK0636027T3 (da) Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
MX9504023A (es) Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
CA2140927A1 (en) Platelet aggregation inhibitors
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
CA2198580A1 (en) Combination therapy to treat osteoporosis
CA2279184A1 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis
GR3034142T3 (en) Composition for the treatment or prevention of herpes
HUP9801894A2 (hu) Dofetilid alkalmazása kongesztív szívpanaszok kezelésére szolgáló gyógyszerkészítmények előállítására
KR950010896A (ko) 근시의 예방 및 치료용 조성물
MY133222A (en) Method of treating glaucoma and ischemic retinopathy
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
CA2153570A1 (en) Pharmaceutical composition for treating nicotine dependence

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees